A survey of 600 US paediatric prescribers found that confidence about state laws was one of the strongest predictors of whether clinicians had treated adolescents with buprenorphine.
A new survey of US paediatric prescribers suggests that the main obstacle to buprenorphine treatment for adolescents with opioid use disorder is not a lack of medical knowledge, but uncertainty over the rules. Researchers writing in BMC Pediatrics found that clinicians who had already prescribed the medicine to patients under 18 were much more confident about the legal landscape than those who had not, and that clarity about the law was one of the strongest predictors of whether a clinician had ever prescribed it.
The study, led by Francine R. Vega at the University of Texas Health Science Center at Houston, drew on anonymous online responses from 600 physicians, nurse practitioners and physician assistants who were authorised to prescribe opioids or medication for opioid use disorder and were treating children or teenagers. The researchers examined five areas: awareness of the law, clinical knowledge, confidence in prescribing, concerns about parental consent and beliefs about medications for opioid use disorder. Their analysis suggested that the type of clinician mattered less than the environment in which care was delivered, with legal clarity, practice setting and beliefs about treatment all shaping whether buprenorphine had ever been used for an adolescent patient.
One of the most striking findings was a mismatch between perceived awareness and actual certainty. Clinicians who had never prescribed buprenorphine to a minor were more likely to say they were aware of the laws, yet they were also more likely to be unsure what those laws allowed in practice. In the survey, a larger share of non-prescribers said they did not know whether their state restricted buprenorphine prescribing for minors. The authors said that pattern suggests knowledge of the existence of rules is not the same as understanding what they mean at the bedside.
After adjusting for clinician type, practice setting and years in practice, the researchers found that greater legal clarity roughly doubled the odds of having prescribed buprenorphine to an adolescent. Male clinicians were also more likely to have prescribed, while working in an office-based group practice and being in certain career stages were associated with lower odds than solo practice and mid-career experience. The authors said the finding on parental consent was unexpectedly tied to prescribing history, which they interpreted as a sign that clinicians who have worked through consent issues in real cases may be more willing to treat despite the complexity.
The policy context helps explain why the survey matters. In 2023, the federal MAT Act removed the X-waiver requirement for buprenorphine prescribing, meaning clinicians with standard DEA registration authority can prescribe the drug for opioid use disorder as long as state law permits it. But federal easing has not removed the patchwork of state rules on minor consent, confidentiality and parental involvement. Some states allow adolescents to consent to substance use treatment on their own, while others require parental participation or leave the boundaries unclear, creating exactly the kind of ambiguity that can discourage treatment in busy primary care or emergency settings.
That ambiguity matters because the treatment gap for young people remains wide. A study discussed in AAP Grand Rounds found that buprenorphine dispensing among US youths aged 19 and under remained low and fell over the period from 2015 to 2020, with paediatricians accounting for only a tiny fraction of all prescriptions each year. Public health groups including The Pew Charitable Trusts and the Milbank Memorial Fund have argued that administrative burdens, reimbursement problems, stigma and confusing prescribing rules all make it harder for clinicians to offer low-threshold treatment in community settings.
The BMC Pediatrics team was careful to note that its sample was recruited through snowball sampling, so it may not reflect every US paediatric prescriber, and that the results show association rather than cause. Even so, the pattern points to practical steps that could widen access quickly: clearer state guidance, better advice on consent and confidentiality, and support for practice teams that are unsure how to start treatment. For adolescents with opioid use disorder, the study suggests the barrier is often not disbelief in the medicine itself, but hesitation created by uncertainty around the law.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
